Comparison of Single- and Three-fraction Schedules of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-Small-cell Lung Cancer

Overview

Journal Clin Lung Cancer

Publisher Elsevier

Specialties Oncology
Pulmonary Medicine

Date 2017 Nov 21

PMID 29153897

Citations 17

Authors

Sung Jun Ma

Lucas M Serra

Yusef A Syed

Gregory M Hermann

Jorge A Gomez-Suescun

Anurag K Singh

Affiliations

Soon will be listed here.

Abstract

Background: To compare the clinical outcomes of patients with early-stage non-small-cell lung cancer (NSCLC) who had undergone either single-fraction (SF) or three-fraction (TF) stereotactic body radiation therapy (SBRT) at a single institution during over 8-year period.

Patients And Methods: Patients with peripherally located early-stage NSCLC who had undergone SBRT from February 2007 to November 2015 were included in the present study. SBRT was delivered without heterogeneity correction. Data were retrospectively reviewed and collected in an institutional review board-approved database. R software (version 3.3.2) was used for statistical analysis.

Results: Of 159 total lung tumors, 65 lesions received 30 Gy (median, 30 Gy) in 1 fraction, and 94 lesions received 48 to 60 Gy (median, 60 Gy) in 3 fractions. Patients with a Karnofsky performance status < 80 were more common in the SF-SBRT cohort (P = .050). After a median follow-up of 22.2 and 26.2 months for the SF-SBRT and TF-SBRT cohorts, respectively (P = .29), no statistically significant difference was found in overall survival (P = .86), progression-free survival (P = .95), local failure (P = .95), nodal failure (P = .91), and distant failure (P = .49) at 24 months. At 1 and 2 years, the overall survival rates were 86.1% and 63.2% for the SF-SBRT cohort and 80.8% and 61.6% for the TF-SBRT cohort, respectively. At 1 and 2 years, the local control rates were 95.1% and 87.8% for the SF-SBRT cohort and 92.7% and 86.2% for the TF-SBRT cohort, respectively. Both regimens were well tolerated.

Conclusion: Despite more patients with poor performance status in the SF-SBRT cohort, the SF- and TF-SBRT regimens showed no differences in clinical outcomes. SF-SBRT is now our standard approach.

Citing Articles

Long-Term Survival and Failure Outcomes of Single-Fraction Stereotactic Body Radiation Therapy in Early Stage NSCLC.

Iovoli A, Prasad S, Ma S, Fekrmandi F, Malik N, Fung-Kee-Fung S JTO Clin Res Rep. 2023; 4(12):100598.

PMID: 38124792 PMC: 10730364. DOI: 10.1016/j.jtocrr.2023.100598.

An optimal dose-fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early-stage non-small lung cancer.

Zarebska I, Harat M Thorac Cancer. 2023; 14(28):2813-2820.

PMID: 37691151 PMC: 10542466. DOI: 10.1111/1759-7714.15071.

Association of neutrophil-lymphocyte ratio with survival in peripheral early-stage non-small cell lung cancer after stereotactic body radiation therapy.

Huang K, Prasad S, Ma S, Yu H, Iovoli A, Farrugia M BMC Cancer. 2023; 23(1):254.

PMID: 36932396 PMC: 10024425. DOI: 10.1186/s12885-023-10719-3.

Comparison of stereotactic body radiotherapy and radiofrequency ablation for early-stage non-small cell lung cancer: a systematic review and meta-analysis.

Zhang R, Kang J, Ren S, Xing L, Xu Y Ann Transl Med. 2022; 10(2):104.

PMID: 35282118 PMC: 8848429. DOI: 10.21037/atm-21-6256.

Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done.

Bartl A, Mahoney M, Hennon M, Yendamuri S, Videtic G, Stephans K Cancers (Basel). 2022; 14(3).

PMID: 35159057 PMC: 8834253. DOI: 10.3390/cancers14030790.

References

Le Q, Loo B, Ho A, Cotrutz C, Koong A, Wakelee H . Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol. 2007; 1(8):802-9. View

Spratt D, Wu A, Adeseye V, Din S, Shaikh F, Woo K . Recurrence Patterns and Second Primary Lung Cancers After Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer: Implications for Surveillance. Clin Lung Cancer. 2015; 17(3):177-183.e2. PMC: 4887418. DOI: 10.1016/j.cllc.2015.09.006. View

Samuels M, Kandula S, Koru-Sengul T, Bogart J, Salama J, Aridgides P . Stereotactic body radiotherapy in patients with stage I non-small-cell lung cancer aged 75 years and older: retrospective results from a multicenter consortium. Clin Lung Cancer. 2013; 14(4):446-51. DOI: 10.1016/j.cllc.2013.03.004. View

Fritz P, Kraus H, Muhlnickel W, Hammer U, Dolken W, Engel-Riedel W . Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases. Radiat Oncol. 2006; 1:30. PMC: 1579222. DOI: 10.1186/1748-717X-1-30. View

Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K . Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007; 2(7 Suppl 3):S94-100. DOI: 10.1097/JTO.0b013e318074de34. View

Fakiris A, McGarry R, Yiannoutsos C, Papiez L, Williams M, Henderson M . Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009; 75(3):677-82. DOI: 10.1016/j.ijrobp.2008.11.042. View

Guy J, Bertoletti L, Magne N, Rancoule C, Mahe I, Font C . Venous thromboembolism in radiation therapy cancer patients: Findings from the RIETE registry. Crit Rev Oncol Hematol. 2017; 113:83-89. DOI: 10.1016/j.critrevonc.2017.03.006. View

Milano M, Zhang H, Usuki K, Singh D, Chen Y . Definitive radiotherapy for stage I nonsmall cell lung cancer: a population-based study of survival. Cancer. 2012; 118(22):5572-9. DOI: 10.1002/cncr.27589. View

Chang J, Senan S, Paul M, Mehran R, Louie A, Balter P . Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015; 16(6):630-7. PMC: 4489408. DOI: 10.1016/S1470-2045(15)70168-3. View

10.

Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I . Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009; 27(20):3290-6. DOI: 10.1200/JCO.2008.21.5681. View

11.

Bral S, Gevaert T, Linthout N, Versmessen H, Collen C, Engels B . Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial. Int J Radiat Oncol Biol Phys. 2010; 80(5):1343-9. DOI: 10.1016/j.ijrobp.2010.04.056. View

12.

Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K . Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys. 2015; 93(5):989-96. DOI: 10.1016/j.ijrobp.2015.07.2278. View

13.

Beitler J, Badine E, El-Sayah D, Makara D, Friscia P, Silverman P . Stereotactic body radiation therapy for nonmetastatic lung cancer: an analysis of 75 patients treated over 5 years. Int J Radiat Oncol Biol Phys. 2006; 65(1):100-6. DOI: 10.1016/j.ijrobp.2005.11.028. View

14.

Nyman J, Johansson K, Hulten U . Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer--mature results for medically inoperable patients. Lung Cancer. 2005; 51(1):97-103. DOI: 10.1016/j.lungcan.2005.08.011. View

15.

Nyman J, Hallqvist A, Lund J, Brustugun O, Bergman B, Bergstrom P . SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol. 2016; 121(1):1-8. DOI: 10.1016/j.radonc.2016.08.015. View

16.

Videtic G, Stephans K, Woody N, Reddy C, Zhuang T, Magnelli A . 30 Gy or 34 Gy? Comparing 2 single-fraction SBRT dose schedules for stage I medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014; 90(1):203-8. DOI: 10.1016/j.ijrobp.2014.05.017. View

17.

Videtic G, Hu C, Singh A, Chang J, Parker W, Olivier K . A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys. 2015; 93(4):757-64. PMC: 4744654. DOI: 10.1016/j.ijrobp.2015.07.2260. View

18.

Zhang J, Yang F, Li B, Li H, Liu J, Huang W . Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol Biol Phys. 2011; 81(4):e305-16. DOI: 10.1016/j.ijrobp.2011.04.034. View

19.

Ma S, Syed Y, Rivers C, Gomez Suescun J, Singh A . Comparison of single- and five-fraction schedules of stereotactic body radiation therapy for central lung tumours: a single institution experience. J Radiother Pract. 2019; 16(2):148-154. PMC: 6358274. DOI: 10.1017/S1460396917000061. View

20.

Bradley J, El Naqa I, Drzymala R, Trovo M, Jones G, Denning M . Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant. Int J Radiat Oncol Biol Phys. 2009; 77(4):1146-50. DOI: 10.1016/j.ijrobp.2009.06.017. View